Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229504 | 0.82 | CYP11B1 (0.42) | ERN1ABL1 | |
| SCHEMBL3751615 | 0.78 | L3MBTL1 (0.41) | — | |
| SCHEMBL13229105 | 0.78 | PIM1 (0.32) | PIM1PIM3 | |
| SCHEMBL12256738 | 0.71 | NQO2 (0.44) | — | |
| SCHEMBL13229239 | 0.71 | ERN1 (0.42) | ERN1NEK1ABL1 | |
| SCHEMBL15158579 | 0.70 | NEK1 (0.32) | ERN1NEK1 | |
| SCHEMBL13229225 | 0.70 | ADRA2A (0.39) | ERN1NEK1PIM1 | |
| SCHEMBL3751633 | 0.68 | PARP1 (0.46) | — | |
| SCHEMBL31285023 | 0.66 | CYP2A6 (0.33) | — | |
| SCHEMBL31285075 | 0.66 | MRGPRX1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501747-B2 | Functionally selective alpha2C adrenoreceptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197562-A1 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRB3 | ERN1 4100/4885NEK1 3176/4885PIM1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.